曲妥珠单抗联合化疗治疗HER2阳性乳腺癌经济性的系统综述

摘要

Objective: To systematically evaluate the pharmacoeconomic vaule of Trastuzumab in adjuvant breast cancer therapy for HER2-positive breast cancer.Methods: A systematic literature search of cost-effectiveness studies on Trastuzumab in adjuvant breast cancer therapy for HER2-positive breast cancer published from 2003 to 2013 was carried out in PubMed, Science Direct, Springer Link and some other database.The studies were screened according to inclusion criteria and the systematic review was conducted according to Pharmacoeconomic methods.Results:The ICER of Trastuzumab in adjuvant breast cancer therapy for HER 2-positive breast cancer was$34307~126933/QALY in America, and C=35975~52753/QALY in Sweden, C=8148~162417/LYS in Norway and C=17000/LYG in Japan.Conclusion:Studies concerning the cost-effectiveness of traztuzumab for HER 2 positive breast cancer patients have not reached consistent conclusions.In the 15 literatures included , 4 of them concluded that Trastuzumab is not a cost-effective therapy with ICER a-bove the implemented willingness-to-pay thresholds.%目的：对曲妥珠单抗联合化疗治疗HER2阳性乳腺癌的药物经济学进行系统分析。方法：计算机检索PubMed、Sci-enceDirect、SpringerLink等数据库2003～2013年间已发表的药物经济学文献，按照一定标准进行筛选，根据药物经济学方法，进行系统综述。结果：曲妥珠单抗治疗的增量成本效果比（ICER）值，美国在34307～126933美元/质量调整生命年（QALY），瑞典为35975～52753欧元/QALY，挪威需要多付出8148～162417欧元/挽救生命年（ LYS），日本为17000欧元/LYG。结论：曲妥珠单抗联合化疗治疗HER2阳性乳腺癌是否具有经济性的研究结论不一致。在15篇研究中，有4篇研究认为曲妥珠单抗联合化疗方案不具有成本-效果。